610.9 USD
-7.14 (-1.16%)
610.9 USD
0 (0%)
Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 57 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is growing strongly while it is still valued neutral. This is a good combination! These ratings could make MEDP a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year MEDP was profitable.
- MEDP had a positive operating cash flow in the past year.
- In the past 5 years MEDP has always been profitable.
- In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of MEDP (24.70%) is better than 100.00% of its industry peers.
- Looking at the Return On Equity, with a value of 147.46%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- The Return On Invested Capital of MEDP (91.45%) is better than 100.00% of its industry peers.
- MEDP had an Average Return On Invested Capital over the past 3 years of 38.75%. This is significantly above the industry average of 13.75%.
- The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
- MEDP has a Profit Margin of 18.36%. This is amongst the best in the industry. MEDP outperforms 92.98% of its industry peers.
- In the last couple of years the Profit Margin of MEDP has grown nicely.
- MEDP has a Operating Margin of 21.50%. This is amongst the best in the industry. MEDP outperforms 89.47% of its industry peers.
- MEDP's Operating Margin has improved in the last couple of years.
- MEDP has a worse Gross Margin (31.11%) than 70.18% of its industry peers.
- In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
- MEDP has less shares outstanding than it did 1 year ago.
- MEDP has less shares outstanding than it did 5 years ago.
- There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- MEDP has an Altman-Z score of 8.52. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 8.52, MEDP belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.52 |
ROIC/WACC8.29
WACC11.03%
2.3 Liquidity
- A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
- MEDP has a Current ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 94.74% of its industry peers.
- A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
- The Quick ratio of MEDP (0.57) is worse than 92.98% of its industry peers.
- The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.22% over the past year.
- Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
- Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 13.88% in the last year.
- The Revenue has been growing by 19.62% on average over the past years. This is quite good.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
- MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.31% yearly.
- MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.31% yearly.
EPS Next Y19.52%
EPS Next 2Y15.37%
EPS Next 3Y13.96%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.12%
Revenue Next 5Y12.31%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 42.72 indicates a quite expensive valuation of MEDP.
- The rest of the industry has a similar Price/Earnings ratio as MEDP.
- MEDP is valuated expensively when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- MEDP is valuated quite expensively with a Price/Forward Earnings ratio of 36.34.
- Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than 63.16% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, MEDP is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.72 | ||
| Fwd PE | 36.34 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as MEDP.
- Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.43 | ||
| EV/EBITDA | 31.6 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of MEDP may justify a higher PE ratio.
- A more expensive valuation may be justified as MEDP's earnings are expected to grow with 13.96% in the coming years.
PEG (NY)2.19
PEG (5Y)1.29
EPS Next 2Y15.37%
EPS Next 3Y13.96%
5. Dividend
5.1 Amount
- MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
610.9
-7.14 (-1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-22 2025-10-22/amc
Earnings (Next)02-09 2026-02-09/amc
Inst Owners87.1%
Inst Owner Change0.69%
Ins Owners0.44%
Ins Owner Change-7%
Market Cap17.21B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target553.98 (-9.32%)
Short Float %6.34%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.26%
PT rev (3m)27.9%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)11.44%
EPS NY rev (1m)0.01%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.72 | ||
| Fwd PE | 36.34 | ||
| P/S | 7.3 | ||
| P/FCF | 25.43 | ||
| P/OCF | 24.2 | ||
| P/B | 58.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.6 |
EPS(TTM)14.3
EY2.34%
EPS(NY)16.81
Fwd EY2.75%
FCF(TTM)24.02
FCFY3.93%
OCF(TTM)25.25
OCFY4.13%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.19
PEG (5Y)1.29
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.52 |
F-Score8
WACC11.03%
ROIC/WACC8.29
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.52%
EPS Next 2Y15.37%
EPS Next 3Y13.96%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.12%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 42.72 and the Price/Book (PB) ratio is 58.61.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.